Sylvie Bertholet is currently head of In Vivo  Immunology at Novartis Vaccines & Diagnostics (NVD) Italy, responsible for the immunological characterization of next generation Staphylococcus aureus and influenza vaccines. She has over 20 years of experience in infectious diseases and vaccine development. She received her PhD in Immunology from the University of Lausanne, Switzerland, and completed her Postdoctoral training at the University of Lausanne and at the National Institutes of Health in Bethesda, studying host-pathogen interactions. Prior to joining NVD, she held position at the Infectious Disease Research Institute in Seattle leading  Tuberculosis,  Pneumococcus  and  Leishmania  vaccine  development  projects.  She  has  authored  more  than  40  publications  on  infectious  disease  and  vaccine-related topics. Sylvie Bertholet is currently head of In Vivo  Immunology at Novartis Vaccines & Diagnostics (NVD) Italy, responsible for the immunological characterization of next generation Staphylococcus aureus and influenza vaccines. She has over 20 years of experience in infectious diseases and vaccine development. She received her PhD in Immunology from the University of Lausanne, Switzerland, and completed her Postdoctoral training at the University of Lausanne and at the National Institutes of Health in Bethesda, studying host-pathogen interactions. Prior to joining NVD, she held position at the Infectious Disease Research Institute in Seattle leading  Tuberculosis,  Pneumococcus  and  Leishmania  vaccine  development  projects.  She  has  authored  more  than  40  publications  on  infectious  disease  and  vaccine-related topics.

Immunology